` YMAB (Y-mAbs Therapeutics Inc) vs S&P 500 Comparison - Alpha Spread

YMAB
vs
S&P 500

Over the past 12 months, YMAB has underperformed S&P 500, delivering a return of -61% compared to the S&P 500's 9% growth.

Stocks Performance
YMAB vs S&P 500

Loading
YMAB
S&P 500
Add Stock

Performance Gap
YMAB vs S&P 500

Loading
YMAB
S&P 500
Difference
www.alphaspread.com

Performance By Year
YMAB vs S&P 500

Loading
YMAB
S&P 500
Add Stock

Competitors Performance
Y-mAbs Therapeutics Inc vs Peers

S&P 500
YMAB
ABBV
AMGN
GILD
VRTX
Add Stock

Y-mAbs Therapeutics Inc
Glance View

Market Cap
209.5m USD
Industry
Biotechnology

Y-mAbs Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer. The company is headquartered in New York City, New York and currently employs 148 full-time employees. The company went IPO on 2018-09-21. The company is focused on development and commercialization of antibody based therapeutic products for the treatment of cancer. The Company’s technologies include bispecific antibodies generated using the Y-BiClone platform and the SADA platform. The Company’s product pipeline includes DANYELZA (naxitamab-gqgk), which targets tumors that express GD2, and omburtamab, which targets tumors that express B7-H3. DANYELZA, which is a humanized monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF) for the treatment of in the bone or bone marrow stable disease to prior therapy and being evaluated for the treatment of other GD2-positive tumors. The company also develops Omburtamab, which is novel murine monoclonal antibody targeting B7-H3. The firm is conducting Phase II clinical trials for the treatment of patients with first-line NB, third-line NB, and in relapsed osteosarcoma.

YMAB Intrinsic Value
9.01 USD
Undervaluation 49%
Intrinsic Value
Price
Back to Top